Daily Respiratory Research Analysis
Analyzed 188 papers and selected 3 impactful papers.
Summary
Three high-impact respiratory studies stood out: a phase 3 trial showed inhaled treprostinil slowed lung function decline and reduced clinical worsening in idiopathic pulmonary fibrosis; a multicenter randomized trial demonstrated that 1.1‑mm cryoprobe transbronchial biopsy improves diagnostic yield over forceps without excess complications; and an individual patient–data analysis across five RCTs identified interleukin‑6 reduction as a mediator of mortality benefit in acute lung injury/COVID-19 interventions.
Research Themes
- Antifibrotic and vasodilatory inhaled therapies for interstitial lung disease
- Innovation in bronchoscopic tissue acquisition
- Inflammation biomarkers as mechanistic mediators and potential therapeutic targets
Selected Articles
1. Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
In TETON‑1 (n=598), inhaled treprostinil reduced 52‑week FVC decline versus placebo (difference 130 mL; P<0.001) and lowered clinical worsening events (HR 0.67). Safety was acceptable with cough as the most common adverse event; effects were consistent in combined analyses.
Impact: This large, double-blind phase 3 RCT demonstrates clinically meaningful preservation of lung function and fewer worsening events in IPF, potentially informing guideline updates and add‑on therapy decisions.
Clinical Implications: Consider inhaled treprostinil as an add‑on to background antifibrotics to slow FVC decline and reduce clinical worsening in IPF, while monitoring cough and adherence given higher discontinuation rates.
Key Findings
- 52-week median FVC change: −43.3 mL with treprostinil vs −196.2 mL with placebo (difference 130.1 mL; 95% CI 82.2–178.1; P<0.001).
- Clinical worsening reduced: 31.8% vs 44.5% (HR 0.67; 95% CI 0.52–0.88; P=0.003).
- No significant difference in time to IPF exacerbation; cough was the most frequent adverse event (54.8% vs 33.1%).
Methodological Strengths
- Double-blind, randomized, placebo-controlled, multicenter phase 3 design with prespecified multiplicity control.
- Large sample with high proportion on background antifibrotics, enhancing external validity.
Limitations
- High discontinuation rates (40.5% vs 32.8%), primarily due to adverse events, may affect estimands.
- Secondary endpoint hierarchy halted after nonsignificant IPF exacerbation result; limited inference on other secondaries.
Future Directions: Define responder subgroups (e.g., baseline physiology, concomitant antifibrotics), optimize dosing/titration to mitigate cough, and evaluate long‑term outcomes (exacerbations, survival) and cost‑effectiveness.
BACKGROUND: Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism. TETON-2 was completed first, and results were published; the results of TETON-1 and of both trials combined are reported here. METHODS: In the double-blind TETON-1 trial, we randomly assigned patients with IPF to receive inhaled treprostinil or placebo (12 breaths four times daily). The primary end point was the change in forced vital capacity (FVC) at week 52. Secondary end points, which were analyzed in a prespecified order to control for multiplicity, were clinical worsening (the first occurrence of death from any cause, hospitalization for a respiratory cause, or a relative decline of ≥10% in the percentage of predicted FVC) and acute exacerbation of IPF (each assessed in a time-to-event analysis), survival, change in percentage of predicted FVC, quality of life, and change in diffusion capacity of the lungs for carbon monoxide at week 52. RESULTS: A total of 598 patients underwent randomization and received at least one dose of treprostinil (299 patients) or placebo (299 patients). Of these, 434 completed the assessments through week 52 (218 in the treprostinil group and 216 in the placebo group). The mean age of the patients was 73.0 years, 77.3% were men, and 77.6% were receiving background antifibrotic therapy; the percentage of predicted FVC at baseline was 74.6%. The median change in FVC at week 52 was -43.3 ml (95% confidence interval [CI], -92.1 to -9.1) with treprostinil and -196.2 ml (95% CI, -227.1 to -155.6) with placebo (difference, 130.1 ml; 95% CI, 82.2 to 178.1; P<0.001). Clinical worsening occurred in 95 patients (31.8%) with treprostinil and in 133 patients (44.5%) with placebo (hazard ratio, 0.67; 95% CI, 0.52 to 0.88; P = 0.003). No significant difference was observed in the time to an IPF exacerbation, and no further inferences regarding secondary end points were made. The most frequent adverse event was cough (reported in 54.8% of the patients in the treprostinil group and 33.1% patients in the placebo group). Discontinuation of treprostinil or placebo occurred in 40.5% and 32.8% of the patients, respectively, with adverse event being the primary reason (20.7% and 14.7%). Efficacy and safety outcomes were similar in analyses of the combined trial data. CONCLUSIONS: In patients with IPF, treatment with inhaled treprostinil led to a smaller decline in FVC and fewer clinical-worsening events than placebo over the course of 52 weeks. (Funded by United Therapeutics; TETON-1 ClinicalTrials.gov number, NCT04708782.).
2. Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial.
In 500 randomized patients, 1.1‑mm cryoprobe transbronchial biopsy achieved higher diagnostic yield than 2.0‑mm forceps (88.6% vs 78.8%), with advantages in nodules/masses and lung transplant recipients and no increase in serious complications.
Impact: This pragmatic, multicenter RCT provides high‑level evidence that cryobiopsy improves diagnostic yield across key bronchoscopic indications, likely shifting standard practice and tissue acquisition protocols.
Clinical Implications: Adopt 1.1‑mm cryoprobe for transbronchial biopsy, particularly for pulmonary nodules/masses and lung transplant surveillance, while maintaining pneumothorax precautions and training for retrieval techniques.
Key Findings
- Primary diagnostic yield: 88.6% (cryoprobe) vs 78.8% (forceps); absolute difference 9.8% (95% CI 3.3–16.3; P=0.003).
- Higher yield with cryobiopsy in nodules/masses (83.2% vs 70.1%; P=0.04) and lung transplant (96.0% vs 88.7%; P=0.03).
- Safety: 0 pneumothoraces (cryoprobe) vs 4 (1.6%) in forceps; no significant bleeding or respiratory failure events.
Methodological Strengths
- Multicenter randomized design with outcome assessor masking and prespecified secondary analyses.
- Broad inclusion across indications (nodules/masses, transplant, diffuse parenchymal lung disease) enhances generalizability.
Limitations
- Open-label operators could introduce performance bias despite assessor masking.
- Limited power for diffuse parenchymal lung disease subgroup; external validation in non-US settings needed.
Future Directions: Standardize cryobiopsy protocols (freeze time, number of passes), evaluate cost‑effectiveness, and compare with larger forceps and novel single‑use devices across diverse centers.
IMPORTANCE: Bronchoscopic biopsy is conventionally performed with forceps, which can result in small specimen sizes and poor specimen quality due to crush artifact. Cryoprobe use localizes freezing at the probe tip, enabling retrieval of larger, more intact biopsy specimens. OBJECTIVE: To evaluate the diagnostic yield of a 1.1-mm cryoprobe for transbronchial biopsy. DESIGN, SETTING, AND PARTICIPANTS: This open-label, outcome assessor-masked, multicenter randomized clinical trial included 500 patients aged 18 years or older scheduled to undergo transbronchial biopsy for lung nodules or masses, lung transplant, or diffuse parenchymal lung disease. The trial was conducted in 9 US medical centers and enrolled patients between February 27, 2023, and September 11, 2024. The date of last follow-up was October 12, 2024. INTERVENTION: Patients were randomized 1:1 to transbronchial biopsy using a 1.1-mm cryoprobe (n = 250) or 2.0-mm forceps (n = 250). MAIN OUTCOMES AND MEASURES: The primary outcome was diagnostic yield, defined as the percentage of patients for whom the transbronchial biopsy sample led to a specific diagnosis based on histologic examination. Of the 8 prespecified secondary analyses, key secondary analyses were the diagnostic yield for each of the 3 conditions (lung nodules or masses, lung transplant, and diffuse parenchymal lung disease) and complication rates. RESULTS: Of 774 patients assessed for eligibility, 609 provided consent, 500 were randomized, and 490 were included in the primary analysis; the mean age was 62.6 years (SD, 12.7 years) and 252 of 500 (50.4%) were male. The primary outcome of diagnostic yield was significantly higher in patients randomized to transbronchial biopsy with cryoprobes vs forceps (217 of 245 [88.6%] vs 193 of 245 [78.8%]; absolute difference, 9.8%; 95% CI, 3.3%-16.3%; P = .003). For the key secondary analyses, compared with that of forceps, the diagnostic yield of cryoprobes was significantly higher among patients with pulmonary nodules or masses (79 of 95 [83.2%] vs 68 of 97 [70.1%]; absolute difference, 13.1%; 95% CI, 1.0%-24.6%; P = .04) and lung transplant (120 of 125 [96.0%] vs 110 of 124 [88.7%]; absolute difference, 7.3%; 95% CI, 0.6%-14.4%; P = .03) but did not differ significantly in diffuse parenchymal lung disease (18 of 25 [72.0%] vs 15 of 24 [62.5%]; absolute difference, 9.5%; 95% CI, -16.0% to 33.6%; P = .55). For the secondary safety analysis, there were 4 pneumothoraces requiring chest tube placement in the forceps group (1.6%) vs none in the cryoprobe group; no patients experienced significant bleeding or respiratory failure events. CONCLUSIONS AND RELEVANCE: Transbronchial lung biopsy performed with a 1.1-mm cryoprobe had a significantly higher diagnostic yield compared with 2.0-mm forceps in a group of patients with lung nodules or masses, lung transplant, and diffuse parenchymal lung disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05751278.
3. Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.
Across five RCTs (n=2563), reductions in IL‑6 mediated survival benefits of imatinib, anakinra, and low tidal volume ventilation, whereas higher PEEP and simvastatin did not modify IL‑6 trajectories. Elevated IL‑6 consistently associated with higher 28‑day mortality (pooled HR 4.83 per log10 increase).
Impact: This IPD mediation analysis provides mechanistic evidence that mortality benefits of specific ARDS/COVID-19 interventions operate via IL‑6 reduction, elevating IL‑6 from a prognostic marker to a plausible therapeutic response biomarker.
Clinical Implications: Monitoring IL‑6 trajectories could help identify responders to anti‑inflammatory strategies (e.g., IL‑1 blockade) and reinforce lung‑protective ventilation; trials could target IL‑6–guided escalation/de‑escalation.
Key Findings
- IL‑6 mediated survival benefits for imatinib, anakinra, and low tidal volume ventilation in joint mediation models.
- High PEEP and simvastatin did not change IL‑6 trajectories, suggesting lack of mediation via IL‑6.
- Higher IL‑6 levels were associated with increased 28‑day mortality (pooled HR 4.83 per log10 increase; 95% CI 3.50–6.66).
Methodological Strengths
- Individual patient data from five large RCTs with repeated biomarker measures and joint modeling for mediation.
- Random‑effects meta‑analysis to synthesize IL‑6–mortality association across studies.
Limitations
- Secondary mediation analysis subject to residual confounding and assumptions (no unmeasured mediator–outcome confounders).
- Heterogeneous interventions and patient populations; causality for IL‑6 as a treatment target requires prospective testing.
Future Directions: Prospective IL‑6–guided treatment algorithms, integration with other inflammatory markers (IL‑8, TNFR1, CRP), and interventional studies targeting IL‑6 dynamics.
RATIONALE: Inflammation in acute respiratory distress syndrome (ARDS) and COVID-19 causes disruption of the alveolar-capillary barrier and tissue damage, which has been associated with increased mortality. Elevated pro-inflammatory plasma biomarkers (specifically interleukin-6) levels reflect the degree of systemic inflammation, and are linked to severity of lung injury. Understanding the causal pathway between inflammation, interventions, and patient outcomes could improve clinical care. OBJECTIVES: To assess IL-6 as a mediator of effective interventions in ARDS and COVID-19. METHODS: We leveraged individual patient data from five large randomized controlled trials. Interventions were imatinib, anakinra, low tidal volume ventilation, high positive end-expiratory pressure (PEEP), and simvastatin. We evaluated IL-6 as a mediator for the effectiveness of interventions on 28-day survival with joint modeling. Additionally, we analyzed the role of other pro-inflammatory markers (IL-8, TNFR1, and CRP). The association between IL-6 and mortality was meta-analyzed using a random effects model. MEASUREMENTS AND MAIN RESULTS: For 2563 patients, IL-6 measures were available at baseline and at least one other timepoint. IL-6 mediated the effects of imatinib, anakinra, and low tidal volume on mortality. Higher PEEP and simvastatin did not alter IL-6 trajectories. In all studies, there were associations between higher IL-6 concentrations and increased mortality over 28 days (pooled HR for a log10 unit increase = 4·83, 95% CI: 3·50 to 6·66). CONCLUSIONS: . The mortality benefit by Anakinra and Imatinib in COVID-19 and low tidal volume ventilation in acute lung injury may operate through resolution of inflammation defined by a reduction in plasma IL-6 levels.